Polli E, Cortellaro M, Parrini L, Tessari L, Chériè Lignière G
Minerva Med. 1975 Dec 5;66(83):4443-59.
After some preliminary remarks of a biochemical and pharmacological nature, the authors have started a clinical study to test the antiinflammatory activity of the S-adenosyl-methionine (SAMe). An open trial, carried out on 90 patients with severe degenerative arthropathies has shown that 30 mg SAMe intravenously twice a day for 14 days have a marked anti-inflammatory effect a rather term and no side-effects. In a "double-crossover" investigation, SAMe was next compared to indomethacin by i.m. administrations to 15 arthropathic patients. The therapeutic responses of the two drugs proved exactly alike, whereas the side-effects following indomethacin administration were not present after SAMe. In 9 patients affected with rheumatoid arthritis administrations of SAMe have proved less effective, although some clinical parameters showed improvements.
在进行了一些生物化学和药理学方面的初步论述后，作者开展了一项临床研究，以测试S-腺苷甲硫氨酸（SAMe）的抗炎活性。一项针对90例严重退行性关节病患者的开放试验表明，每天静脉注射30毫克SAMe，共14天，具有显著的抗炎作用，且持续时间较长，并且没有副作用。在一项“双交叉”研究中，接下来将SAMe与消炎痛进行了比较，对15例关节病患者进行肌肉注射给药。结果证明两种药物的治疗反应完全相同，而消炎痛给药后出现的副作用在使用SAMe后并未出现。在9例类风湿性关节炎患者中，SAMe的给药效果较差，尽管一些临床参数有所改善。
